Up and coming Queensland life sciences firms headed back to the USA recently for the next phase of a unique program designed to accelerate their entry into the North American market.

Representatives from De Motu CordisField Orthopaedics, Microba and Zucero Therapeutics travelled to San Francisco for mentoring and networking as part of the FAST Queensland Advisory Program.

FAST is run by TIQ in conjunction with Life Sciences Queensland and the California Life Sciences Institute, and includes coaching in market analysis, legal requirements, pitching and finance, as well as opportunities to meet with potential investors.

The most recent visit to the USA included a major networking event with potential investors, organised by TIQ and AusBiotech in conjunction with the high-profile JP Morgan Healthcare Conference.

Zucero Executive Chairman Chris Burrell said that the FAST program presented unique opportunities to promote the company’s lead innate immune activating small molecule, ZU545, to a North American audience.

‘The advice and assistance received from our advisors over the term of the FAST program has put us in a much stronger position in terms of our story and understanding the uniqueness of the North American market,’ he said.

Queensland Trade and Investment Commissioner for North America Viki Forrest said that the participating medtech firms were world-class in their fields and deserved an international platform.

‘FAST is a way to help fast-track globally relevant medtech developments coming out of Queensland by connecting them to the networks and potential financial support available in the USA,’ she said.

‘We’re continuing to work with the companies and looking forward to their participation at the BIO International Convention in San Diego in June.’

Supporting Queensland exporters is a priority under the Queensland Trade and Investment Strategy 2017–2022.

If you’re considering exporting to the USA, connect with TIQ today.

|